
Cooper Companies (COO) Stock Forecast & Price Target
Cooper Companies (COO) Analyst Ratings
Bulls say
Cooper Companies is well-positioned in the eyecare and women's health industries, with its strong portfolio of contact lenses and medical devices for women's health and fertility. Despite challenges in the APAC region, the company is still expected to see mid-single digit organic revenue growth and high-single digit or better EPS growth due to operating expense leverage and debt reduction. Potential upside drivers include successful product launches, margin improvement, and strategic actions. However, increasing competition in the contact lens market and currency headwinds pose potential risks to the company's performance.
Bears say
Cooper Companies is facing headwinds in both of its segments, CooperVision and CooperSurgical. Revenue growth may be moderate and interest expense may decline, but the company's FY26 FCF has been lowered and its NTM P/E multiple has been reduced to 16.5x in light of recent compression in the medtech space. The company is also facing potential competition in the contact lens market and could see EPS pressure from a new product in its CooperSurgical segment.
This aggregate rating is based on analysts' research of Cooper Companies and is not a guaranteed prediction by Public.com or investment advice.
Cooper Companies (COO) Analyst Forecast & Price Prediction
Start investing in Cooper Companies (COO)
Order type
Buy in
Order amount
Est. shares
0 shares